Acer Therapeutics Inc. announced the promotion of Tanya Hayden to Chief Operating Officer (COO). Harry S. Palmin, who had been serving as the Company's Chief Operating Officer as well as its Chief Financial Officer, will continue to serve as the Company's Chief Financial Officer. In her new role as COO, Ms. Hayden will have primary responsibility for supporting operational and commercial growth and effectiveness, as well as establishing, improving, and scaling the company's executional operations.

Ms. Hayden joined Acer in June 2021 as Vice President of Program and Strategic Alliance Management and has played a critical role in the advancement of Acer's investigational programs, including the Company's ongoing preparations for the potential commercial launch of ACER-001 (sodium phenylbutyrate) for treatment of urea cycle disorders (UCDs), and management of its strategic collaborations. Ms. Hayden will continue to oversee program and strategic alliance management responsibilities in her newrole as COO. Prior to joining Acer, Ms. Hayden spent 20-years at Lonza (formerly Bend Research/Capsugel) and was responsible for businessunit planning, operational excellence, clinical and commercial contract manufacturing, and program management.

Throughout her career, Ms. Hayden has had the opportunity to lead internal cross-functional teams to introduce new capabilities and improve performance, as well as collaborate with external partners to advance new products to the market. Ms. Hayden received a B.S. degree in Chemistry from Gonzaga University.